ASAHI KASEI PHARMA CORPORATION
Value of Glycated Albumin in Intervention of Glycemic Control in Chinese Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2022-02-07
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Asahi Kasei Pharma Corporation
- Target Recruit Count
- 200
- Registration Number
- NCT05227677
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, China
🇨🇳Beijing Pinggu District Hospital, Beijing, China
🇨🇳Beijing Tiantan Hospital, Capital Medical University, Beijing, China
First-In-Human Study of AK1320 Encapsulated Microspheres (AK1320 MS)
- Conditions
- Interventions
- First Posted Date
- 2020-07-23
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Asahi Kasei Pharma Corporation
- Target Recruit Count
- 30
- Registration Number
- NCT04483297
- Locations
- 🇨🇦
Hôpital Sacré-Coeur de Montréal, Montreal, Quebec, Canada
🇨🇦Royal Alexandra Hospital, Edmonton, Alberta, Canada
🇨🇦Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Clinical Study of AK1820 (Isavuconazonium Sulfate) for the Treatment of Deep Mycosis
- First Posted Date
- 2018-03-21
- Last Posted Date
- 2021-05-14
- Lead Sponsor
- Asahi Kasei Pharma Corporation
- Target Recruit Count
- 103
- Registration Number
- NCT03471988
- Locations
- 🇯🇵
Research site, Nagasaki, Japan
Exploratory Study of ART-123 for the Prevention of Cancer Treatment Related Symptoms in Patients With Postoperative Stage II / III Colon Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-06-08
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Asahi Kasei Pharma Corporation
- Target Recruit Count
- 79
- Registration Number
- NCT02792842
Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis
- First Posted Date
- 2016-04-15
- Last Posted Date
- 2019-01-18
- Lead Sponsor
- Asahi Kasei Pharma Corporation
- Target Recruit Count
- 74
- Registration Number
- NCT02739165
Lucica ® Glycated Albumin-L Clinical Program - Pivotal Study
- Conditions
- First Posted Date
- 2015-07-03
- Last Posted Date
- 2019-11-21
- Lead Sponsor
- Asahi Kasei Pharma Corporation
- Target Recruit Count
- 150
- Registration Number
- NCT02489773
- Locations
- 🇺🇸
National Research Institute - Huntington Park, Los Angeles, California, United States
🇺🇸Tulane University, New Orleans, Louisiana, United States
🇺🇸Dallas Diabetes and Endocrine Center, Dallas, Texas, United States
A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Refractory Nephrotic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2014-10-06
- Last Posted Date
- 2019-01-17
- Lead Sponsor
- Asahi Kasei Pharma Corporation
- Target Recruit Count
- 239
- Registration Number
- NCT02257697
- Locations
- 🇨🇳
The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
🇨🇳Wuxi People's Hospital, Wuxi, Jiangsu, China
🇨🇳Shandong Provincial Hospital, Jinan, Shandong, China
A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Lupus Nephritis
- Conditions
- Interventions
- First Posted Date
- 2014-10-03
- Last Posted Date
- 2019-06-07
- Lead Sponsor
- Asahi Kasei Pharma Corporation
- Target Recruit Count
- 250
- Registration Number
- NCT02256150
- Locations
- 🇨🇳
The first Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China
🇨🇳The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China
A Phase I Study of AK159 in Healthy Postmenopausal Women
- First Posted Date
- 2013-09-05
- Last Posted Date
- 2017-02-15
- Lead Sponsor
- Asahi Kasei Pharma Corporation
- Target Recruit Count
- 170
- Registration Number
- NCT01935479
Clinical Pharmacokinetics Study of ART-123 in Disseminated Intravascular Coagulation (DIC) Subjects With Renal Impairment
- First Posted Date
- 2012-10-11
- Last Posted Date
- 2017-02-15
- Lead Sponsor
- Asahi Kasei Pharma Corporation
- Target Recruit Count
- 40
- Registration Number
- NCT01704001